Biotechnology

Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101

May 21, 2025 8:15 AM

Northway Biotech, Inc. ("Northway Biotech"), an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), and Kaida BioPharma ("Kaida" or the "Company"), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced they have entered into a manufacturing agreement for the production of Kaida's lead product candidate, KAD101. Under the...

Read more

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

May 21, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company advancing next-generation immunotherapies, is pleased to announce the appointment of Ralph Hughes as the new Chief Business Officer, starting on the 28 May 2025. Mr. Hughes will be part of the Management Team and Business Development Committee. Prior to joining Faron, Mr. Hughes worked as Senior Vice President at PharmaVentures, serving multiple...

Read more

Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer

May 20, 2025 9:15 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces its partnership with Innolitics, a leading developer in the Software-as-a-Medical Device space. The collaboration is intended to integrate many of the Company's emerging capabilities in the ongoing development of its first-in-industry SaaS...

Read more

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 20, 2025 9:00 AM

Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Dr. Steven Quay, CEO of Atossa Therapeutics. Attendees will gain insight into Atossa's strategic approach to redefining breast cancer treatment...

Read more

Cambridge Isotope Laboratories Launches ISOLED-D: Revolutionary Deuterated Reagents for OLED Manufacturing

May 20, 2025 9:00 AM

Cambridge Isotope Laboratories, Inc. (CIL), the global leader in stable isotope-labeled products, announces the launch of ISOLED-D™, a groundbreaking line of deuterated reagents specifically designed for organic light-emitting diode (OLED) synthesis. ISOLED-D represents a significant advancement in OLED manufacturing technology, offering high-quality deuterated reagents with manufacturing in state-of-the-art, strategically located worldwide...

Read more

Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency

May 20, 2025 8:40 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical stage biotechnology company pioneering immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has granted a waiver from conducting paediatric clinical trials for Alligator's lead asset mitazalimab. The waiver, issued as part of the Paediatric Investigation Plan (PIP) regulatory process, exempts Alligator from the obligation to conduct pediatric studies with...

Read more

Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis

May 20, 2025 8:00 AM

Doron Therapeutics, a clinical-stage biotechnology company focused on regenerative therapies for musculoskeletal diseases, today announced the successful completion of its initial RMAT and End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for MOTYSTM (PTP-001), the company's lead biologic candidate for the treatment of knee osteoarthritis. Key meeting outcomes include: Confirmation of size and scope of Phase 3 clinical...

Read more

Bora Biologics Expands San Diego Facility for 2000L+ Scale Biologics Manufacturing, Boosting CDMO Capacity

May 20, 2025 6:45 AM

Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a...

Read more

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12

May 20, 2025 6:45 AM

Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The exercise period for warrants...

Read more

Repair Biotechnologies Receives Orphan Drug Designation From the FDA for the Treatment of Homozygous Familial Hypercholesterolemia

May 19, 2025 12:00 PM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/) is a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque. The company is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug REP-0003 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), a rare condition of accelerated...

Read more

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 19, 2025 8:05 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built across several commercial-stage medical device and pharmaceutical companies including Biolase,...

Read more

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

May 19, 2025 8:01 AM

Tharimmune, Inc. (Nasdaq:THAR), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced the appointment of James Gordon Liddy (CDR US Navy SEAL (Ret)) as a strategic advisor. Mr. Liddy, an internationally recognized expert on counterterrorism and critical infrastructure protection, will provide invaluable guidance as Tharimmune advances the development of TH104, its lead program for temporary...

Read more

Aspira Announces First Quarter 2025 Financial Results and Provides Business Update

May 19, 2025 7:55 AM

Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team. Key financial highlights for the quarter are summarized below: Revenue...

Read more

Biovica Signs Major Service Agreement and First Study Work Order of 4 MSEK

May 19, 2025 2:45 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces the signing of a Master Service Agreement (MSA) with a US-based pharmaceutical and biotechnology company recognized as a Tier-1 player in oncology. A first work order has also been signed totaling SEK 4 million. Under the agreement, Biovica will provide TKa testing across multiple projects using its DiviTum® TKa...

Read more

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

May 16, 2025 9:25 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's AI-engineered exozymes are reshaping the next generation of biomanufacturing by enabling sustainable chemical production outside of living cells. Considered one of...

Read more

Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation

May 16, 2025 7:30 AM

Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors. The rebranding follows the successful acquisition of AI Maverick...

Read more

Lifeloc Reports First Quarter 2025 Results

May 15, 2025 6:40 PM

Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.277 million resulting in a quarterly net loss of $(293) thousand, or $(0.11) per diluted share. These results compare to net revenue of $2.153 million and...

Read more

Longwood Healthcare Leaders to Convene Top Life Science Executives at Industry-Leading Networking Forum, MIT CEO

May 15, 2025 7:00 AM

Longwood Healthcare Leaders convenes top biopharmaceutical leaders for two days of off-the-record discussion, June 17-18, 2025, at the annual MIT CEO, co-hosted with MIT President Sally Kornbluth, Nobelist Phil Sharp (co-founder Biogen/Alnylam), Bob Langer (co-founder Moderna/Momenta), and Matthew Vander Heiden (Director, Koch Institute), and held at MIT's Koch Institute in Kendall Square, Cambridge, MA. Thought leaders across government,...

Read more

Last Day of Trading in Warrants Series TO 12 in Alligator Bioscience is 15 May 2025

May 15, 2025 2:50 AM

Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. 15 May 2025 is the last day of trading in warrants series TO...

Read more

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

May 15, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be presented at EHA 2025 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announced that data from its ongoing BEXMAB study evaluating bexmarilimab in patients with high-risk...

Read more